clinical trial · NCT05485987
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Friedreich AtaxiaVatiquinone
brief summary
The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
started
Oct 12, 2022
primary completion
Aug 29, 2024
completion
Aug 29, 2024
last updated
Aug 22, 2025
official title
An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol